Pfizer Secures Key Regulatory Win in Cancer Treatment Portfolio

Pharmaceutical giant Pfizer is actively pursuing strategies to offset declining revenue from its COVID-19 products and establish new avenues for growth. A significant development has emerged from its oncology division, providing a potential boost to these efforts. The U.S. Food and Drug Administration (FDA) has granted full approval for a crucial combination therapy targeting colorectal cancer. This regulatory milestone represents a strategic advance, though market observers continue to scrutinize the company’s long-term pipeline strength.

FDA Converts Accelerated Approval to Full Authorization

The agency has converted the accelerated approval for the drug Braftovi into a full authorization. This decision specifically covers its use in the first-line treatment of adults with metastatic colorectal cancer harboring a specific genetic mutation (BRAF V600E). Consequently, Pfizer now markets the only targeted combination therapy approved for this patient population.

This regulatory action is grounded in compelling clinical evidence from the phase 3 BREAKWATER study. The data demonstrated that the combination therapy significantly reduced the risk of death by 51% compared to standard chemotherapy. It also lowered the risk of disease progression or death by 47%. For Pfizer, this success is a fundamental component of its strategy to expand precision oncology as a central growth driver.

A Strategic Pivot Amidst Transition

This regulatory victory arrives at a pivotal moment for the company. Pfizer is navigating a period characterized by patent expirations on legacy blockbuster drugs and the normalization of its COVID-related business segment. Management has reaffirmed its full-year 2026 revenue guidance, projecting a range of $59.5 to $62.5 billion.

Should investors sell immediately? Or is it worth buying Pfizer?

A key metric for investors is the projected operational growth in the core business, which is estimated at approximately 4% when adjusted for COVID product sales and patent losses. To support margins, the company is implementing a rigorous cost-reduction program aimed at achieving billions in savings by the end of the current year.

Mixed Sentiment Persists Among Market Experts

The stock market is monitoring these developments closely. Pfizer shares are currently trading at €22.94, showing modest weekly stability with a gain of 1.39%, though the stock remains in negative territory year-to-date.

Analyst perspectives, however, remain divided. Barclays recently maintained a cautious “Underweight” rating on the equity, emphasizing ongoing risks. In contrast, HSBC sees potential upside, assigning a price target of $29.00. The prevailing market consensus currently leans toward a “Hold” recommendation, as many investors prefer to await tangible progress on the company’s promised pipeline launches.

Attention now turns to the coming week. CEO Albert Bourla is scheduled to speak at a healthcare conference on Monday, March 2, 2026. The investment community anticipates concrete details on how Pfizer plans to fund and execute over 20 planned clinical trial initiations this year, which are critical to securing its long-term growth narrative.